Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Hoffmann-La Roche
Astellas Pharma Inc
QuantumLeap Healthcare Collaborative
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
Aminex Therapeutics, Inc.
Merck Sharp & Dohme LLC
MedSIR
National Institutes of Health Clinical Center (CC)
Genmab
Dana-Farber Cancer Institute
City of Hope Medical Center
Japanese Foundation for Cancer Research
Merck Sharp & Dohme LLC
Tizona Therapeutics, Inc
Essen Biotech
Memorial Sloan Kettering Cancer Center
Baylor Research Institute
University of Virginia
IDEAYA Biosciences
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
Weill Medical College of Cornell University
Eli Lilly and Company
Emory University
Takeda
Dana-Farber Cancer Institute
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
University of Southern California
Big Ten Cancer Research Consortium
University of Chicago
University of California, San Francisco